Norlin Jenny M, Steen Carlsson Katarina, Persson Ulf, Schmitt-Egenolf Marcus
Department of Public Health and Clinical Medicine, Division of Dermatology and Venereology, Umeå University, SE-901 85 Umeå, Sweden.
Acta Derm Venereol. 2015 Feb;95(2):156-61. doi: 10.2340/00015555-1895.
The introduction of biologics has changed treatment patterns as well as costs in patients with psoriasis. This study was performed to estimate direct and indirect costs of the psoriasis population in Sweden, and to analyse changes in costs between 2006 and 2009. The study population was identified in national registers. Direct costs included health care visits with primary psoriasis diagnoses in specialist care and drugs relevant for treating psoriasis. Productivity loss, including costs of long-term sick leave and disability pension, was estimated as the difference between psoriasis patients and matched controls from the general population. Total direct cost increased from SEK 348 million (~ €39) in 2006 to SEK 459 million (~ €51) in 2009, whereas the total productivity loss decreased from SEK 1,646 (~ €183) to 1,618 million (~ €180) between 2006 and 2009. Although direct costs, especially for biologic agents, have increased for patients with psoriasis over time, this study indicates that costs related to productivity loss are still more substantial.
生物制剂的引入改变了银屑病患者的治疗模式和费用。本研究旨在估算瑞典银屑病患者群体的直接和间接费用，并分析2006年至2009年间的费用变化。研究人群通过国家登记册确定。直接费用包括专科护理中初次诊断为银屑病的医疗就诊以及与治疗银屑病相关的药物。生产力损失，包括长期病假和残疾抚恤金的费用，通过银屑病患者与来自普通人群的匹配对照之间的差异来估算。总直接费用从2006年的3.48亿瑞典克朗（约合39欧元）增加到2009年的4.59亿瑞典克朗（约合51欧元），而2006年至2009年间，总生产力损失从16.46亿瑞典克朗（约合183欧元）降至16.18亿瑞典克朗（约合180欧元）。尽管随着时间的推移，银屑病患者的直接费用，尤其是生物制剂的费用有所增加，但本研究表明，与生产力损失相关的费用仍然更为可观。
